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Abstract
Tumor growth is estrogen independent in approximately one-third of all breast cancers, which makes these
patients unresponsive to hormonal treatment. This unresponsiveness to hormonal treatment may be explained
through the absence of the estrogen receptor alpha (ESR1). The ESR1 gene re-expression through epigenetic
modulators such as DNA methyltransferase inhibitors and/or histone deacetylase inhibitors restores tamoxifen
sensitivity in ESR1 negative breast cancer cell lines and opens new treatment horizons in patients who were
previously associated with a poor prognosis.
In the study presented herein, we tested the ability of ribavirin, which shares some structural similarities with the
DNA-methyltransferase inhibitor 5-azacytidine and which is widely known as an anti-viral agent in the treatment of
hepatitis C, to restore ESR1 gene re-expression in ESR1 negative breast cancer cell lines.
In our study we identified ribavirin to restore ESR1 gene re-expression alone and even more in combination with
suberoylanilide hydroxamic acid (SAHA - up to 276 fold induction).
Ribavirin and analogs could pave the way to novel translational research projects that aim to restore ESR1 gene re-
expression and thus the susceptibility to tamoxifen-based endocrine treatment strategies.
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Introduction
Breast cancer is the most frequent type of cancer in
women in the Western world and the second leading
cause of cancer death. Approximately one in 8 women
living in the USA today is being diagnosed with breast
cancer at some point during her lifetime [1].
In the clinic, the estrogen receptor (ESR) and more
precisely the estrogen receptor a (ESR1) is an important
prognostic disease marker [2]. Approximately two-thirds
of breast cancers are ESR1-positive.
The binding of estrogen to the ESR1 is not only a key
regulator for the physiological growth and differentiation
of the mammary gland, it is also a key element in the
malignant progression of breast cancer, i.e. the growth
of ESR1 expressed breast cancer cells is stimulated by
estrogen, which in turn makes it accessible to endocrine
treatment strategies, while breast cancers that do not
express ESR1 exhibit a primary resistance to endocrine
treatment [3,4]. Therefore, the presence of ESR1 corre-
lates with increased disease-free survival and a better
prognosis when compared to ESR1-negative breast can-
cers [5]. While at the time of diagnosis up to one-third
of breast cancers are ESR1 negative, quite a few cancers
that are initially ESR1 positive lose the ESR1 during the
course of tumor progression and are therefore no longer
responsive to endocrine therapy designed to block ESR1
function [6].
While the lack of ESR1 expression appears to be
caused by genetic mutations in only less than 1% of
ESR1-negative cancers, there is increasing evidence that
epigenetic alterations of cytosine residues at the level of
the ESR1 promoter DNA and the posttranslational mod-
ification of N-terminal ends of histone proteins are
responsible for the absence of ESR1 expression in ESR1-
negative cancers [7,8]. Typically, hypermethylation of
CpG elements in the 5’ regulatory region of the ER gene * Correspondence: ulrich.mahlknecht@uks.eu
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negative breast cancers [9].
5-aza-2’-deoxycytidine, which is a cytidine analog leads
to partial demethylation of the ESR promoter and con-
sequently to re-expression of ESR mRNA and synthesis
of functional ESR protein [10]. 5-aza-2’-deoxycytidine
directly and irreversibly binds the DNA methyltransfer-
ase (DNMT), which blocks the DNMT methylating
activity. 5-aza-2’-deoxycytidine is being incorporated
into DNA in the presence of S-adenosylmethionine
(SAM), which is a donor of methyl groups [11].
In addition to the hypomethylation of CpG elements
within the ESR promoter, gene silencing may also be
mediated through the posttranslational deacetylation of
histone proteins, which goes along with a condensation
of the chromatin architecture and therefore the silencing
of associated genes. This inactive, highly condensed
chromatin architecture is structured around hyper-
methylated ESR promoter CpG clusters. Methyl CpG-
binding proteins recruit histone deacetylase (HDAC)
enzymes which consequently deacetylate specific lysine
groups on N-terminal histone ends, preferentially on H3
and H4 histone proteins. This results in a condensed
nucleosome structure on the basis of an ionic interac-
tion between positively charged lysine residues and the
negatively charged DNA that limits transcription
[12-14].
In vitro studies identified the HDAC inhibitor Tri-
chostatin A (TSA) to restore functional ESR1 mRNA
and protein expression in ESR1 negative breast cancer
cells [13]. Also, suberoylanilide hydroxamic acid
(SAHA), an HDAC inhibitor that is used in the clinic
for various indications (e.g. cutaneous T-cell lym-
phoma), was able to re-express ESR1 in addition to its
suppressive effects on the epidermal growth factor sig-
naling pathway [15]. The combination of a DNMT inhi-
bitor (e.g. 5-aza-2’-deoxycytidine) with an HDAC
inhibitor such as TSA goes along with the synergistic
reactivation of functional ESR1 [8]. The re-expression of
ESR1 is by far more effective for the combination of
agents when compared to the single agent treatment
with 5-aza-2’-deoxycytidine or TSA.
Another way to reduce the degree of genomic DNA
methylation is based on the inhibition of the S-adeno-
sylhomocysteine (SAH) hydrolase. SAH, which is the
reactant of the SAH hydrolase, is the demethylated
form of SAM, the methyl donor of DNMT, which on
the other hand, is a powerful inhibitor of methyltras-
ferase enzymes through its competing activity for the
SAM binding site. SAH is further hydrolyzed by SAH
hydrolase to adenosine and homocysteine [16]. The
inhibition of theses enzymes results in increased levels
of SAH, which in turn, inhibits the DNMT enzymes
[17].
In the study presented herein, we report ribavirin to
induce the re-expression of ESR1. Ribavirin inhibits the
inosinate dehydrogenase and is a synthetic oral nucleo-
side analog, that is known since long as an antiviral
agent in the treatment of a broad spectrum of DNA and
RNA viruses, particularly in combination with alpha
interferon for the treatment of chronic hepatitis C [18].
In addition to other effects, ribavirin also inhibits the
SAH hydrolase, which may in fact explain the hypo-
methylation of the ESR promoter DNA and the asso-
ciated re-expression of ESR1 [19]. Also, the chemical
structure of ribavirin is highly similar to the chemical
structure of 5-azycytidine, which inhibits the DNMT
and could therefore also help to explain how hypo-
methylation of the ESR promoter DNA is being asso-
ciated with the re-expression of ESR1 [20].
We show that ribavirin induces the re-expression of
functional ESR1 in the ESR1-negative cells MDA-MB-
231. This effect is strongly potentiated for the combina-
tion of ribavirin with an HDAC inhibitor, which was -
in turn - able to restore the response to tamoxifen
treatment.
Taken together, our data show that the combination
of ribavirin and SAHA induces the re-expression of
functional ESR1 and restores sensitivity of ESR1-nega-
tive cells to endocrine therapies.
Materials and methods
Cell Culture and Treatment Protocols
The human breast cancer cell lines MDA-MB-231, SK-
BR-3 and UACC3199 were all cultured in DMEM. The
medium was supplemented with 10% FBS and 1% peni-
cillin/streptomycin. The cells were grown at 37°C and
5% CO2.
12 h prior to treatment the cells were plated at a den-
sity of 500,000 cells/100 mm tissue culture dishes. After
12 h, the culture medium was changed and the cells
were treated with the reagents as indicated below. Riba-
virin (Sigma-Aldrich, Munich, Germany) was used at
concentrations of 9, 90 and 900 μM, respectively for up
to 8 days. Trichostatin A (TSA, 0.33 μM) (Sigma-
Aldrich, Munich, Germany) or suberoylanilide hydroxa-
mic acid (SAHA, 10 μM) (Sigma-Aldrich, Munich, Ger-
many) were only added during the last 12 h. For the
treatment with 4-OH Tamoxifen (Sigma-Aldrich,
Munich, Germany) the medium was changed to a med-
ium containing 4-OH Tamoxifen (0.1, 1, 10, 20 μM) for
24 h.
RNA Isolation and RT-PCR Analysis of ER Expression
Total cellular RNA was isolated from treated and
untreated cells with RNeasy Mini Kit (Qiagen, Hilden,
Germany). Using high-capacity cDNA archive kit
(Applied Biosystems, Darmstadt, Germany) up to 1 μg
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tion of the cDNA was used for the real-time PCR using
a LightCycler (Roche, Heidelberg, Germany) real-time
PCR analyzer and LightCycler cyber green reagents
(Roche, Heidelberg, Germany). Each reaction contained
2.5 mM MgCl2. The thermal cycling conditions for 45
cycles were 92°C for 15 seconds, 60°C for 1 minute and
72°C for 30 seconds. Specific primers for ESR1 (5’- GCA
CCC TGA AGT CTC TGG AA - 3’,5 ’-T G GC T A
AAG TGG TGC ATG AT -3’)a n dA c t i n( 5 ’- CCA
GCA CAA TGA AGA TCA AGA TC -3’,5 ’- ACA TCT
GCT GGA AGG TGG ACA -3’) were used. Linear
amplification ranges were determined using LightCycler
analysis software and reaction crossing points were
applied to the formula described by Pfaffl [21].
Cell Proliferation
For the determination of the cell count the cells were
plated in medium at a concentration of 500,000 cells/
100 mm tissue culture dishes. After 12 h, the cells were
exposed to the indicated concentration of reagents for
up to 132 h. At defined time points the processed cells
were washed with PBS. After trypsinication the cells
were resuspended in 5 ml fresh serum-containing med-
ium and counted in a hemocytometer. For every time
point three samples were counted in duplicates.
Western Blot Analysis
MDA-MB-231 cells were plated in medium at a concen-
tration of 500,000 cells/100 mm tissue culture dishes.
One group of cells were pretreated with ribavirin (900
μM) and SAHA (10 μM) for 120+12 h while the other
group remained untreated. Cells were then exposed to
the indicated concentrations of 4-OH-Tam for 24 h,
washed with PBS and lysed on ice in lysis buffer (100
m MT r i s - H C l ,p H8 . 5 ,1 0 0m MN a C l ,0 . 5 %N P 4 0 ,1 0 0
μg/ml PMSF). After lysis the cells were centrifuged at
13,000 rpm for 20 minutes at 4°C. Until usage the
supernatants were stored at -20°C. Protein concentra-
tions were quantified by absorption at 280 nm in 1:100
dilutions in 0.1 mM NaOH. 20 μg of total protein were
analyzed under reducing conditions on a 12% polyacry-
lamide gel and blotted onto a nitrocellulose membrane.
The blots were blocked over night in TBST buffer in 5%
non-fat milk. For staining the blots were incubated with
anti-human procaspase 8 polyclonal antibody (1:200),
anti-human procaspase 9 monoclonal antibody (1:200)
and anti-human Actin antibody (1:5000) followed by
incubation with the peroxidase-conjugated anti-goat,
anti-rabbit or anti-mouse antibodies (1:1000). Finally the
blots were washed three times and then visualized with
the ECL chemiluminescent detection system. The rela-
tive protein amount was normalized to Actin. Actin
antibodies were obtained from Sigma-Aldrich
(Heidelberg, Germany). Proc a s p a s e8a n d9a n t i b o d i e s
were purchased from Santa Cruz (Heidelberg, Germany)
(SC-6134 and SC-17784).
Results
Ribavirin-mediated Reactivation of Estrogen Receptor
Gene Expression
In order to explore the effect of Ribavirin on ESR gene
expression, we used the ESR-negative cell line MDA-
MB-231, since recent studies had shown a re-expression
of ESR1 after treatment with hypomethylating agents
[10]. We examined ESR1 expression by RT-PCR after
drug exposure. The ESR-negative cell line was treated
for 72 h with ribavirin at final concentrations of 9; 90
and 900 μM, respectively. A dose dependent increase in
ESR1 mRNA was detected. The maximum ribavirin
dose of 900 μM could not be further increased because
of ribavirin cytotoxicity. At this dose level a 4.5 fold
induction of ESR1 mRNA was reached [Figure 1]. In
order to further determine whether this was already the
peak expression level we studied the ESR1 gene expres-
sion over several time points for up to 120 h. The
increase of ESR1 mRNA induction was time dependent
with a maximum after 120 h. The increase of ESR1
mRNA induction was time dependent with a fold induc-
tion ranging from a minimum of 5.1 to a maximum of
190 (!) after 120 h [Figure 2 and additional file 1]. Since
we were not certain whether we had already reached
peak levels within 120 h, cells were treated for up to 8
days and ESR1 mRNA expression was measured every
other day. In this series ESR1 mRNA expression was
h i g h e s to nd a y6w i t ha4 . 6f o l dE S R 1e x p r e s s i o nv s .
controls [data are not shown, additional file 2]. Along
with earlier results, ribavirin induced ESR1 expression
was identified to peak on day 5 at a final concentration
of 900 μM.
In addition to the MDA-MB-231 cell line two ESR-
negative cell lines were tested. Previous studies had
identified ESR promoter hypermethylation in these two
cell lines, UCCA-3199 andS K - B R - 3[ 2 2 ] .T h eE S R 1
mRNA increase was determined after 5 days of exposure
to 900 μM Ribavirin. Both cell lines responded well to
ribavirin and while we observed only a minimum 1.5
fold induction of ESR1 expression in the UCCA-3199
cell line, a minimum 6.8 fold induction was identified in
the SK-BR-3 cell line [cf. additional file 3].
Previous studies have shown that the hypomethylating
effect may be increased through combination of hypo-
methylating agents with an HDAC inhibitor [8]. In
order to test whether the effect of ribavirin was also
increasable in MDA-MB-231 cells, these were treated
for 72 h with 900 μM ribavirin alone or followed by 12
h of treatment with 10 μMS A H Ao r0 . 3 3μMT S A .
This condition has been shown as the optimal treatment
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Page 3 of 9scheme in previous studies [8]. After treatment the
expression of ESR1 mRNA was measured. A minimum
10.3 fold induction was reached for the combination
with SAHA and a minimum 3.8 fold induction for the
combination with TSA [Figure 3]. After 120 h of
treatment with 900 μM Ribavirin followed by 12 h treat-
ment with 10 μM SAHA the increase of ESR1 mRNA
induction reached a maximum 276 fold induction [cf.
additional file 4]. In accordance with the literature,
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Figure 1 Dose-dependent effect of ribavirin on ESR1 mRNA expression in MDA-MB-231 cells as measured by real-time PCR. Cells were
treated with different doses (9, 90 and 900 μM) of ribavirin for 72 h. The experiment has been done three times. Every experiment has shown
an increase in expression of ESR1- however with a significant variation among the single experiments. A representative experiment is shown.
Figure 2 Time-dependent effect of ribavirin on ESR1 mRNA
expression in MDA-MB-231 cells as measured by real-time PCR.
Cells were treated with 900 μM ribavirin for up to 120 h (n = 3).
Every experiment has shown a time-dependent increase in
expression of ESR1- however with a significant variation among the
single experiments. The experiment with the maximum effect is
shown. The experiment with the minimum response is shown in
supplemental material 1.
Figure 3 The effect of ribavirin alone or in combination with
TSA or SAHA on ESR1 mRNA expression in MDA-MB-231 cells
as measured by real-time PCR. Cells were treated with 900 μM
ribavirin for 72 h alone or followed by 12 h treatment with 10 μM
SAHA or 0.33 μM TSA (n = 3). Every experiment has shown the
same effect as to the expression of ESR1 - however with a
significant variation among the single experiments. A representative
experiment is shown.
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factory results.
Ribavirin Inhibits the Proliferation of MDA-MB-231 Cells
In order to determine the effect of ribavirin on MDA-
MB-231 cell proliferation, cells were regularly counted
on a hemocytometer during treatment with ribavirin.
Cells were exposed to the following conditions: 900 μM
ribavirin, 10 μMS A H Aa n d9 0 0μM ribavirin plus 10
μM SAHA, respectively, counted at 24 h intervals and
compared to the untreated controls. While SAHA alone
had no effect on the cell proliferation, the treatment
with ribavirin alone or in combination with SAHA
inhibited cell proliferation. The calculation of the prolif-
eration factor for ribavirin alone and in combination
with SAHA resulted in a positive growing balance [Fig-
ure 4].
Estrogen Receptor Gene Expression and Cell Growth
Subsequent to Treatment with Ribavirin
In order to determine the duration of ESR1 re-expres-
sion, cells were treated with 900 μM ribavirin for 5
days. Cell culture medium was changed and cell samples
were analyzed on a daily basis. ESR1 mRNA levels were
quantified in relation to untreated cells. The re-expres-
sion of ESR1 mRNA decreased during the observed
treatment course [Figure 5] and reached ESR1 mRNA
levels of untreated cells 72 h after treatment disconti-
nuation. Based on a potentially altered cell growth beha-
vior under treatment, the cell growth was further
determined for up to 5 days after treatment with 900
μM ribavirin and in one treatment arm it was followed
by a 12 h exposure to 10 μM SAHA. After 72 h of treat-
ment the effect of ribavirin on cell growth was no longer
present. The determination of the growth curve and the
proliferation factor showed the same pattern as for
untreated cells, which allows the conclusion that the
effect of ribavirin in the breast cancer cells that have
been studied is reversible[Figure 6].
Figure 4 The effect of ribavirin alone or in combination with
the HDAC inhibitor SAHA in ESR1-negative breast cancer cells
MDA-MB-231 on cell growth is shown. The Figure shows the
growth curves for untreated MDA-MB-231 cells vs. cells that were
treated with 10 μM SAHA for 12 h or treated with 900 μM ribavirin
for up to 120 h or treated with 900 μM ribavirin in combination
with 10 μM SAHA for 12 h to 120 h. Each curve is the average of
three independent experiments.
Figure 5 The effect of ribavirin on ESR1 mRNA expression in
MDA-MB-231 after treatment as measured by real-time PCR.
Cells were treated with 900 μM ribavirin for 120 h. mRNA was
measured after treatment for up to 4 days (n = 3). Every experiment
has shown the same effect as to the expression of ESR1 with a
significant variation among the single experiments. A representative
experiment is shown.
Figure 6 The effect of ribavirin alone or in combination with
SAHA in ESR1-negative breast cancer cells MDA-MB-231 on cell
growth after treatment. The figure demonstrates the growth
curves for MDA-MB-231 cells after treatment with 900 μM ribavirin
alone or in combination with 10 μM SAHA (120 h + 12 h). Cell
numbers were measured after the treatment for up to 4 days. Each
curve is the average of three independent experiments.
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Our study identified ESR expression to peak after 5 days
of treatment with 900 μM ribavirin followed by 12 h of
treatment with 10 μM SAHA. This effect was detectable
for up to 48 h after treatment discontinuation. In order
to further assess the expression of a functional ESR1
protein, cells were exposed to 4-hydroxytamoxifen (4-
OH-Tam) at different concentrations for 24 h subse-
quent to treatment with ribavirin plus SAHA. Apoptosis
was measured by determination of procaspase-8 and the
procaspase-9 levels. To prevent potential interactions
between the agents that were used, the cell culture med-
ium was changed prior to treatment with 4-OH-Tam.
Cells that were treated with the combination of ribavirin
plus SAHA experienced a decrease of procaspase 8
levels subsequent to treatment with 20 μM 4-OH-Tam,
which indicated increased apoptosis in the presence of
4-OH-Tam subsequent to re-expression of a functional
ESR protein which sensitized the cells to 4-OH-Tam
treatment [Figure 7].
Discussion
In this report we demonstrate ribavirin to induce
expression of the ESR1 both, on the RNA and the func-
tional levels.
The presence of the ESR is an important prognostic
indicator as to the responsiveness of breast cancer to an
endocrine therapy. The lack of ESR expression (more
precisely ESR1) is the predominant mechanism that has
been ascribed to de novo endocrine treatment resistance
[4]. In less than 1% the loss of ESR1 expression results
from genetic mutations [7]. In addition, earlier studies
have shown that the absence of ESR may also be the
result of aberrant epigenetic modifications, such as the
deacetylation of histones and methylation of DNA at the
level of the ESR promoter [23]. The treatment of ESR-
negative breast cancer cells with hypomethylating
agents, such as 5-azacytidine or 5-aza-2’-deoxycytidine
has been reported to go along with the re-expression of
functionally active ESR [10]. 5-aza-2’-deoxycytidine
induces the re-expression of ESR by inhibition of the
DNA methyltransferase (DNMT) through irreversible
binding of the DNMT [11].
In the study presented herein, we show ribavirin to
induce the re-expression of functionally active ESR1 in
ESR-negative breast cancer cells.
Based on structural similarities with 5-azycytidine,
ribavirin was chosen in order to assess for potential
hypomethylating functional activities on ESR1 expres-
sion. Ribavirin is a known inhibitor of the S-adenosyl-L-
homocysteine (SAH) hydrolase [19]. Inhibition of the
SAH hydrolase goes along with increased levels of SAH,
which in turn, is a potent inhibitor of the DNMT [17].
Our data show a dose dependent up regulation of ESR1
at the mRNA level upon treatment with ribavirin [Fig-
ure 1], which peaks at concentrations of 900 μM. This
in vitro concentration equals to the 100-fold concentra-
tion of the mean steady state plasma concentration after
four weeks of treatment with 600 mg ribavirin being
administered twice daily [24].
This increase is also time dependent with a peak on
day 5 [Figure 2 and additional files].
Numerous studies have shown previously that the
effect of hypomethylating agents such as 5-aza-2’-deoxy-
cytidine may be potentiated by co-treatment with an
HDAC inhibitor (e.g. TSA or SAHA) [8,25]. In this
study we explored whether the combination of ribavirin
with TSA or SAHA would go along with similar effects.
The treatment agents were administered sequentially:
the cells were treated with 900 μM ribavirin over 3 days
first, which was followed by a 12 h treatment with 10
μMS A H Ao r0 . 3 3μM TSA, which resulted in an up
regulation of the ESR1 mRNA expression. This effect
was more pronounced for SAHA than for TSA and sug-
gested a synergistic effect for the combination of riba-
virin with HDAC inhibitors. Similar synergistic effects
have also been observed for combinations of 5-azacyti-
dine with HDAC inhibitors [Figure 3].
Several studies have reported that both, the hypo-
methylation through 5-aza-2’-deoxycytidine and HDAC
inhibition through TSA inhibit the growth of breast can-
cer cells either alone or in combination [26-28]. We
observed that treatment with ribavirin alone or in com-
bination with SAHA inhibits the growth of the breast
cancer cells, while SAHA alone has no effect. Ribavirin
alone or in combination with TSA had similar effects
[Figure 4].
Since earlier studies had pointed out that the effect of
5-azacytidine was the result from an irreversible binding
to the DNMT [29,30]. We were wondering whether this
was also true for ribavirin. 48 h after the end of the
treatment with ribavirin or ribavirin in combination
with SAHA the cells grew just like the untreated con-
trols and we were able to observe a decrease in the
ESR1 mRNA expression [Figures 5, 6], which led us to
the conclusion that the effect of ribavirin was reversible.
In order to further explore whether the re-expressed
ESR was functionally active, we treated our cells with 4-
hydroxytamoxifen (4-OHTam), which is the active meta-
bolite of tamoxifen and observed an adequate response
to endocrine therapy, which was in accordance with ear-
lier studies, which showed the sensitization of estrogen-
negative breast cancer cells to endocrine therapy after
treatment with 5-aza-2’-deoxycytidine in combination
with TSA [28]. In cells that were pretreated with a com-
bination of ribavirin plus SAHA we were able to see an
induction of apoptosis at concentration of 20 μM4 -
OHTam, as assessed by adecreased level of procaspase-
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Page 6 of 9Figure 7 E f f e c to fr i b a v i r i ni nc o m b i n a t i o nw i t hSAHA in ESR1-negative breast cancer cells MDA-MB-231 on tamoxifen sensitivity.
Western blot analyses of procaspase 8 and 9 are shown after 24 h of treatment with different concentrations of 4-OHTam. They were either
pretreated with 900 μM ribavirin in combination with 10 μM SAHA or remained untreated MDA-MB-231 cells. b-Actin was probed as the loading
control. The decrease of procaspase levels is an indication of increased apoptosis, which is being caused by pretreatment with ribavirin and
SAHA. A representative experiment is shown.
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231 cells re-express a functionally active ESR1 subse-
quent to treatment with Ribavirin and SAHA [Figure 7].
In summary, this study leads us to the conclusion that
that functionally active ESR1 can be re-expressed in
estrogen-negative breast cancer cells by treatment with
ribavirin and SAHA, which restores the sensitivity to 4-
OHTam endocrine treatment. Ribavirin and analogs
could therefore pave the way to the development of
novel therapeutic strategies, which aim at the re-expres-
sion of ESR in order to restore the susceptibility to
tamoxifen-related treatment regimens.
Additional material
Additional file 1: Time-dependent effect of ribavirin on ESR1 mRNA
expression in MDA-MB-231 cells as measured by real-time PCR. Cells
were treated with 900 μM ribavirin for up to 120 h. The experiment with
the minimum effect is shown.
Additional file 2: The time-dependent effect of ribavirin on ESR1
mRNA expression in MDA-MB-231 cells as measured by real-time
PCR. Cells were treated with 900 μM ribavirin for up to 8 days. The
maximum effect on ESR1 mRNA was observed on day 6 (n = 3). Every
experiment has shown a time-dependent increase in expression of ESR1.
The results varied significantly. A representative experiment is shown.
Additional file 3: Effect of ribavirin on different ESR1 negative
breast cancer cells as measured by real-time PCR. MDA-MB-231,
UACC-3199 and SK-BR-3 cells were treated with 900 μM ribavirin for 5
days. A representative example of two experiments that yielded similar
results is shown.
Additional file 4: Time-dependent effect of ribavirin in combination
with SAHA on ESR1 mRNA expression in MDA-MB-231 cells as
measured by real-time PCR. Cells were treated with 900 μM of ribavirin
for up to 120 h followed by a 12 h treatment with 10 μM SAHA (n = 3).
Every experiment has shown a time-dependent increase as to the
expression of ESR1. The experiments varied strongly. The experiment
with the maximum effect is shown.
Abbreviations
ESR1: estrogen receptor alpha; HDAC: histone deacetylase; DNMT: DNA
methyltransferase; SAHA: suberoylanilide hydroxamic acid; TSA: Trichostatin
A; 4-OHTam: 4-hydroxytamoxifen; SAH: S-adenosylhomocysteine; SAM: S-
adenosylmethionine.
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